Caris Life Sciences

01/29/2026

Attending the Liquid Biopsy for Precision Oncology Summit?
Join Matthew Oberley, MD, PhD, Chief Clinical Officer at Caris Life Sciences, for a session on how WES-based reporting is expanding to include pharmacogenomic and emerging biomarkers, how CHIP-aware liquid biopsy interpretation improves variant confidence, and real-world case studies. Learn more: https://ow.ly/lCJf50Y5sUs

01/28/2026

A study published in Nature’s npj Breast Cancer journal uncovered clinically relevant mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer.

“This study demonstrates how population scale, multiomic real world data can drive high impact translational discoveries, reinforcing the value proposition for patients and equipping biopharma with actionable insights into resistance biology to guide next generation drug development,” said David Spetzler, MS, PhD, MBA, Caris President.

Learn more: https://ow.ly/sERr50Y4yQZ

01/27/2026

January is Cervical Cancer Awareness Month. Learn how Caris' comprehensive molecular profiling identifies targeted treatment for cervical cancer patients. https://ow.ly/E3Ii50Y44cu

01/21/2026

Join Caris at the NRG Oncology Winter Meeting in San Francisco.
Stop by booth 5 to meet our team and discover how our advanced molecular profiling solutions are helping redefine cancer care. Learn more: https://bit.ly/4gOuelO

01/19/2026

Lung cancer survivor and advocate Maggie McCloskey was diagnosed with stage IV lung cancer in 2021. Through comprehensive molecular profiling with Caris Life Sciences, she found hope and empowerment. Today, she mentors others and shares why personalized medicine matters.

Learn more: https://ow.ly/ARoe50XxSu8

01/12/2026

Caris Life Sciences and Everlywell are partnering to launch Caris Detect, Caris’ forthcoming Multi-Cancer Early Detection (MCED) blood-based screening assay, through Everlywell’s platform.

“By combining our advanced precision medicine technologies with Everlywell’s consumer-focused platform, we’re creating a powerful new pathway for people to detect cancer at its earliest and most treatable stages, before it can spread, ultimately supporting better outcomes for patients, ” said Caris President David Spetzler, MS, PhD, MBA.

Learn more: https://ow.ly/aue050XUpxF

01/12/2026

Caris Life Sciences announces preliminary, unaudited financial results for the fourth quarter and full year ended D​e​c​e​m​b​er 31, 2​0​2​5. Learn more: https://ow.ly/sZgn50XUprI

01/09/2026

EGFR mutations are critical markers in NSCLC. MI Cancer Seek is FDA-approved to detect the most common mutations, including exon 19 deletions and exon 21 L858R, helping physicians personalize treatment.

Learn how MI Cancer Seek supports therapy decisions in NSCLC: https://bit.ly/4lyGNTR

01/08/2026

Attending the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco? Stop by Booth 86 to meet with our experts and learn what Caris has in store for the future of precision medicine. Learn more: https://ow.ly/kb8a50XTsVW

01/05/2026

Caris Life Sciences will present at the 44th Annual J.P. Morgan Healthcare Conference, which will be held January 12-15, 2026, in San Francisco, California.

Learn more: https://ow.ly/cZs450XQElM

01/01/2026

Happy New Year from everyone at Caris. We wish you a joyful 2026!

12/26/2025

Elevate precision care with liquid biopsy from Caris Assure, an innovative multi-cancer assay that provides deep molecular insights from a simple blood sample. Explore how this powerful liquid biopsy assay can revolutionize patient care. Learn more: https://ow.ly/Ohce50XNSha

Caris Assure® is a liquid biopsy that provides a minimally invasive blood test for comprehensive molecular analysis of tumor biomarkers, guiding personalized cancer therapy.